Association of Lipoprotein Lipase Gene Variation With Coronary Artery Disease | Cardiology | JAMA | The JAMA Network
March 7, 2017
Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease
Amit V. Khera, MD1,2,3; Hong-Hee Won, PhD4; Gina M. Peloso, PhD1,5; et alColm O’Dushlaine, PhD6; Dajiang Liu, PhD7; Nathan O. Stitziel, MD, PhD8,9,10; Pradeep Natarajan, MD1,2,3; Akihiro Nomura, MD1,2,3; Connor A. Emdin, DPhil1,2,3; Namrata Gupta, PhD1; Ingrid B. Borecki, PhD6; Rosanna Asselta, PhD11,12; Stefano Duga, PhD11,12; Piera Angelica Merlini, MD13; Adolfo Correa, MD14; Thorsten Kessler, MD15,16; James G. Wilson, MD17; Matthew J. Bown, MD18; Alistair S. Hall, MD19; Peter S. Braund, PhD18; David J. Carey, PhD20; Michael F. Murray, MD20; H. Lester Kirchner, PhD20; Joseph B. Leader, BA20; Daniel R. Lavage, BS20; J. Neil Manus, BS20; Dustin N. Hartzel, BS20; Nilesh J. Samani, MD18; Heribert Schunkert, MD16; Jaume Marrugat, MD, PhD21; Roberto Elosua, MD, PhD21; Ruth McPherson, MD22; Martin Farrall, FRCPath23,24; Hugh Watkins, MD, PhD23,24; Eric S. Lander, PhD1; Daniel J. Rader, MD25; John Danesh, FMedSci26,27,28,29; Diego Ardissino, MD30,31; Stacey Gabriel, PhD1; Cristen Willer, PhD32,33,34; Gonçalo R. Abecasis, PhD35; Danish Saleheen, MD29; Frederick E. Dewey, MD6; Sekar Kathiresan, MD1,2,3; for the Myocardial Infarction Genetics Consortium, DiscovEHR Study Group, CARDIoGRAM Exome Consortium, and Global Lipids Genetics Consortium
Author Affiliations
JAMA. 2017;317(9):937-946. doi:10.1001/jama.2017.0972
FullText
Key Points
Question Do heterozygous carriers of a damaging mutation in the gene encoding lipoprotein lipase have increased odds of coronary artery disease?
Findings In this cross-sectional study of coronary artery disease case-control studies, gene sequencing identified a damaging mutation in the lipoprotein lipase gene in 188 of 46 891 individuals (0.4%). These mutations were associated with an increase of 19.6 mg/dL in plasma triglycerides and an increased presence of coronary artery disease.
Meaning The presence of rare damaging mutations in the lipoprotein lipase gene was significantly associated with higher triglyceride levels and presence of coronary artery disease; however, further research is needed to assess whether this association is causal, including possible mechanisms by which heterozygous lipoprotein lipase deficiency could lead to coronary artery disease.
Abstract
Importance The activity of lipoprotein lipase (LPL) is the rate-determining step in clearing triglyceride-rich lipoproteins from the circulation. Mutations that damage the LPL gene (LPL) lead to lifelong deficiency in enzymatic activity and can provide insight into the relationship of LPL to human disease.
Objective To determine whether rare and/or common variants in LPL are associated with early-onset coronary artery disease (CAD).
Design, Setting, and Participants In a cross-sectional study, LPL was sequenced in 10 CAD case-control cohorts of the multinational Myocardial Infarction Genetics Consortium and a nested CAD case-control cohort of the Geisinger Health System DiscovEHR cohort between 2010 and 2015. Common variants were genotyped in up to 305 699 individuals of the Global Lipids Genetics Consortium and up to 120 600 individuals of the CARDIoGRAM Exome Consortium between 2012 and 2014. Study-specific estimates were pooled via meta-analysis.
Exposures Rare damaging mutations in LPL included loss-of-function variants and missense variants annotated as pathogenic in a human genetics database or predicted to be damaging by computer prediction algorithms trained to identify mutations that impair protein function. Common variants in the LPL gene region included those independently associated with circulating triglyceride levels.
Main Outcomes and Measures Circulating lipid levels and CAD.
Results Among 46 891 individuals with LPL gene sequencing data available, the mean (SD) age was 50 (12.6) years and 51% were female. A total of 188 participants (0.40%; 95% CI, 0.35%-0.46%) carried a damaging mutation in LPL, including 105 of 32 646 control participants (0.32%) and 83 of 14 245 participants with early-onset CAD (0.58%). Compared with 46 703 noncarriers, the 188 heterozygous carriers of an LPL damaging mutation displayed higher plasma triglyceride levels (19.6 mg/dL; 95% CI, 4.6-34.6 mg/dL) and higher odds of CAD (odds ratio = 1.84; 95% CI, 1.35-2.51; P < .001). An analysis of 6 common LPL variants resulted in an odds ratio for CAD of 1.51 (95% CI, 1.39-1.64; P = 1.1 × 10−22) per 1-SD increase in triglycerides.
Conclusions and Relevance The presence of rare damaging mutations in LPL was significantly associated with higher triglyceride levels and presence of coronary artery disease. However, further research is needed to assess whether there are causal mechanisms by which heterozygous lipoprotein lipase deficiency could lead to coronary artery disease.
https://phgkb.cdc.gov/GAPPKB/phgHome.do
Last Posted: Mar 08, 2017
Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease 
AV Khera et al, JAMA, March 7, 2017
Keys to Your Genetic Heart Health
AC Sturm, NSGC Blog Post, March 2017
Appropriate Use of Genetic Testing in Congenital Heart Disease Patients.
Ito Seiji et al. Current cardiology reports 2017 Mar 19(3) 24
Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.
et al. JAMA oncology 2017 Feb
ScreenPro FH - Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Rationale and Design.
Ce?ka Richard et al. Vnitrni lekarstvi 2017 63(1) 43-48
Advances in the Genetics of Congenital Heart Disease: A Clinician's Guide.
Blue Gillian M et al. Journal of the American College of Cardiology 2017 Feb 69(7) 859-870
Advances in the Genetics of Congenital Heart Disease- A Clinician’s Guide
GM Blue et al, JACC< February 2017
Cardiovascular disease prevention: lifestyle attenuation of genetic risk
BJ Arsenault et al, Nature Rev Cardiology, February 2017
A Valentine for You, from Cardiovascular Genetic Counselors
My Gene Counsel, February 9, 2017
The role of registries and genetic databases in familial hypercholesterolemia.
Kindt Iris et al. Current opinion in lipidology 2017 Feb
Using Workflow Modeling to Identify Areas to Improve Genetic Test Processes in the University of Maryland Translational Pharmacogenomics Project.
Cutting Elizabeth M et al. AMIA ... Annual Symposium proceedings. AMIA Symposium 2015466-74
A Valentine for You, from Cardiovascular Genetic Counselors
My Gene Counsel, February 9, 2017
PCOS and Diabetes, Heart Disease, Stroke...
6 Reasons to Talk to Your Family About Heart Disease
Genetics of Congenital Heart Disease: Past and Present.
Muntean Iolanda et al. Biochemical genetics 2016 Nov
Why Are Young, Fit People Dying From Heart Disease?
By Anna Medaris Miller, Health US News, February 2, 2017
more